The Effects of Low-Dose Erythropoiesis-Stimulating Agents on Peritoneal Fibrosis Induced by Chemical Peritonitis and on Peritoneal Tissue MMP–2 and TIMP–2 Levels in Rats

REFERENCES

• Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int. 2003; 23: 530–541
   PubMed Web of Science ®Google Scholar
• Miyata T, Devusyst O, Kurukowa K, Van Ypersele de Strihou C. Toward beter dialysis compatibility advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int. 2002; 61: 375–386
   PubMedGoogle Scholar
• Dobbie JW, Anderson JD. Ultrastructure, distribution, and density of lamellar bodies in human peritoneum. Perit Dial Int. 1996; 16: 482–487
   PubMedGoogle Scholar
• Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006; 69: 1806–1813
   PubMed Web of Science ®Google Scholar
• Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000; 97: 10526–10531
   PubMed Web of Science ®Google Scholar
• Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003; 100: 4802–4806
   PubMed Web of Science ®Google Scholar
• Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol. 2005; 25: 64–76
   PubMedGoogle Scholar
• Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: Role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol. 2007; 18: 1497–1507
   PubMed Web of Science ®Google Scholar
• Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci. 2006; 101: 31–39
   PubMedGoogle Scholar
• Ishii Y, Sawada T, Shimizu A, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant. 2001; 16: 1262–1266
   PubMedGoogle Scholar
• Sis B, Sarioglu S, Sokmen S, et al. Desmoplasia measured by computer assisted image analysis: An independent prognostic marker in colorectal carcinoma. J Clin Pathol. 2005; 5: 32–38
   Google Scholar
• Sarioglu S, Sis B, Celik A, et al. Quantitative digital histochemistry with methenamine silver staining in renal allograft biopsies excluding pure chronic allograft nephropathy cases. Transplant Proc. 2006; 38: 490–491
   PubMed Web of Science ®Google Scholar
• Sis B, Sarioglu S, Celik A, et al. Renal medullary changers in renal allograft recipients with raised serum creatinine. J Clin Pathol. 2006; 59: 377–381
   PubMedGoogle Scholar
• Sokmen S, Lebe B, Sarioglu S, et al. Prognostic value of CD44 expression in colorectal carcinomas. Anticancer Res. 2001; 21: 4121–4126
   PubMed Web of Science ®Google Scholar
• Hirahara I, Inoue M, Okuda K, et al. The potential of matrix metalloproteinase–2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis—a multicentre study in Japan. Nephrol Dial Transplant. 2007; 22: 560–567
   PubMed Web of Science ®Google Scholar
• Hirahara I, Umeyama K, Shofuda K, et al. Increase of matrix metalloproteinase–2 in dialysate of rat sclerosing encapsulating peritoneal model. Nephrology 2002; 7: 161–169
   Google Scholar
• Ersoy R, Celik A, Yilmaz O, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int. 2007; 27: 424–431
   PubMed Web of Science ®Google Scholar
• Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006; 69: 1806–1813
   PubMed Web of Science ®Google Scholar
• Mondello S, Mazzon E, Di Paola R, et al. Erythropoietin suppresses peritoneal fibrosis in rat experimental model. Eur J Pharmacol. 2009; 604: 138–149
   PubMedGoogle Scholar
• Martin J, Yung S, Robson RL, et al. Production and regulation of matrix metalloproteinases and their inhinbitors by human peritoneal mesotelial cells. Perit Dial Int. 2000; 20: 524–533
   PubMed Web of Science ®Google Scholar
• Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995; 77: 863–868
   PubMed Web of Science ®Google Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res. 2002; 90: 251–262
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274: 21491–21494
   PubMed Web of Science ®Google Scholar